Zydus Cadila has received the final approval from the US Food and Drug Administration (FDA) to market Clobetasol Propionate Ointment USP, 0.05%. The drug is indicated to treat variety of skin conditions (e.g., eczema, dermatitis, allergies, rash). It will be manufactured at the group's Topical manufacturing facility at Ahmedabad.
The group now has more than 165 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.
Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.
